Advertisement

Clinical Drug-Drug Interaction Data: Effects of Co-administered Drugs on Pharmacokinetics of Antiretroviral Agents

  • Tony K. L. Kiang
  • Kyle John Wilby
  • Mary H. H. Ensom
Chapter

Abstract

This chapter summarizes the clinical drug-drug interaction data for each antiretroviral agent. The effects of co-administered drugs on the pharmacokinetics of the following agents will be presented:
  • Nonnucleoside reverse transcriptase inhibitors (NNRTIs): delavirdine, efavirenz, etravirine, nevirapine, and rilpivirine

  • Nucleoside reverse-transcriptase inhibitors (NRTIs): abacavir, didanosine, and zidovudine

  • Protease inhibitors (PIs): atazanavir, darunavir, fosamprenavir, emtricitabine, lamivudine, stavudine, tenofovir, indinavir, nelfinavir, ritonavir, saquinavir, tipranavir, and lopinavir

  • Fusion Inhibitors: enfuvirtide

  • Entry inhibitors: maraviroc

  • Integrase inhibitors: dolutegravir, elvitegravir, raltegravir

Keywords

Pharmacokinetic Interaction CYP450 Enzyme Tenofovir Disoproxil Fumarate CYP3A4 Inhibitor CYP3A4 Inducer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2016; Available at: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0. Accessed 19 June 2016
  2. 2.
    McCance-Katz EF, Moody DE, Morse GD, Friedland G, Pade P, Baker J et al (2006) Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin Infect Dis 43(Suppl 4):S224–S234PubMedCrossRefGoogle Scholar
  3. 3.
    Voorman RL, Maio SM, Payne NA, Zhao Z, Koeplinger KA, Wang X (1998) Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A. J Pharmacol Exp Ther 287(1):381–388PubMedGoogle Scholar
  4. 4.
    Kobayashi K, Yamamoto T, Chiba K, Tani M, Shimada N, Ishizaki T et al (1998) Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos 26(8):818–821PubMedGoogle Scholar
  5. 5.
    Rescriptor (2012) Prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf. Accessed 19 June 2016
  6. 6.
    Ito K, Ogihara K, Kanamitsu S, Itoh T (2003) Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 31(7):945–954PubMedCrossRefGoogle Scholar
  7. 7.
    Borin MT, Cox SR, Herman BD, Carel BJ, Anderson RD, Freimuth WW (1997) Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients. Antimicrob Agents Chemother 41(9):1892–1897PubMedPubMedCentralGoogle Scholar
  8. 8.
    Niwa T, Shiraga T, Takagi A (2005) Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 28(9):1805–1808PubMedCrossRefGoogle Scholar
  9. 9.
    Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW (1997) Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin Pharmacol Ther 61(5):544–553PubMedCrossRefGoogle Scholar
  10. 10.
    Borin MT, Chambers JH, Carel BJ, Freimuth WW, Aksentijevich S, Piergies AA (1997) Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients. Antiviral Res 35(1):53–63PubMedCrossRefGoogle Scholar
  11. 11.
    Ferry JJ, Herman BD, Carel BJ, Carlson GF, Batts DH (1998) Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers. J Acquir Immune Defic Syndr Hum Retrovirol 18(3):252–259PubMedCrossRefGoogle Scholar
  12. 12.
    Morse GD, Fischl MA, Shelton MJ, Cox SR, Driver M, DeRemer M et al (1997) Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 41(1):169–174PubMedPubMedCentralGoogle Scholar
  13. 13.
    Sustiva (2008) Prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020972s030,021360s019lbl.pdf. Accessed 19 June 2016
  14. 14.
    Burt HJ, Galetin A, Houston JB (2010) IC50-based approaches as an alternative method for assessment of time-dependent inhibition of CYP3A4. Xenobiotica 40(5):331–343PubMedCrossRefGoogle Scholar
  15. 15.
    Williamson B, Dooley KE, Zhang Y, Back DJ, Owen A (2013) Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. Antimicrob Agents Chemother 57(12):6366–6369PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Ji P, Damle B, Xie J, Unger SE, Grasela DM, Kaul S (2008) Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects. J Clin Pharmacol 48(8):948–956PubMedCrossRefGoogle Scholar
  17. 17.
    Sekar VJ, De Pauw M, Marien K, Peeters M, Lefebvre E, Hoetelmans RM (2007) Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers. Antivir Ther 12(4):509–514PubMedGoogle Scholar
  18. 18.
    Arya V (2005) Clinical pharmacology and biopharmaceutics review (21–976). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021976s000_Sprycel_ClinPharmR.pdf. Accessed 6 June 2016
  19. 19.
    Kumar GN, Rodrigues AD, Buko AM, Denissen JF (1996) Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 277(1):423–431PubMedGoogle Scholar
  20. 20.
    Eagling VA, Back DJ, Barry MG (1997) Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44(2):190–194PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Lillibridge JH, Liang BH, Kerr BM, Webber S, Quart B, Shetty BV et al (1998) Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos 26(7):609–616PubMedGoogle Scholar
  22. 22.
    Granfors MT, Wang JS, Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT (2006) Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol 98(1):79–85PubMedCrossRefGoogle Scholar
  23. 23.
    Liu L, Mugundu GM, Kirby BJ, Samineni D, Desai PB, Unadkat JD (2012) Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LC-MS/MS cocktail assays and RT-PCR. Biopharm Drug Dispos 33(4):207–217PubMedCrossRefGoogle Scholar
  24. 24.
    Kakuda TN, DeMasi R, van Delft Y, Mohammed P (2013) Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial. HIV Med 14(7):421–429PubMedCrossRefGoogle Scholar
  25. 25.
    Intelence (2009) Prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022187s002lbl.pdf. Accessed 19 June 2016
  26. 26.
    Kakuda TN, Van Solingen-Ristea R, Aharchi F, Smedt GD, Witek J, Nijs S et al (2013) Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers. J Clin Pharmacol 53(1):41–50PubMedCrossRefGoogle Scholar
  27. 27.
    Yanakakis LJ, Bumpus NN (2012) Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism. Drug Metab Dispos 40(4):803–814PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Hammond KP, Wolfe P, Burton JR Jr, Predhomme JA, Ellis CM, Ray ML et al (2013) Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers. J Acquir Immune Defic Syndr 62(1):67–73PubMedCrossRefGoogle Scholar
  29. 29.
    Ogilvie BW, Yerino P, Kazmi F, Buckley DB, Rostami-Hodjegan A, Paris BL et al (2011) The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos 39(11):2020–2033PubMedCrossRefGoogle Scholar
  30. 30.
    Chu X, Cai X, Cui D, Tang C, Ghosal A, Chan G et al (2013) In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters. Drug Metab Dispos 41(3):668–681PubMedCrossRefGoogle Scholar
  31. 31.
    Ernest CS 2nd, Hall SD, Jones DR (2005) Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 312(2):583–591PubMedCrossRefGoogle Scholar
  32. 32.
    Viramune (2010) Prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020933s022,020636s032lbl.pdf. Accessed 19 June 2016
  33. 33.
    Edurant (2015) Prescribing information. Available at: http://www.edurant.com/shared/product/Edurant/EDURANT-PI.pdf. Accessed 19 June 2016
  34. 34.
    Lade JM, Avery LB, Bumpus NN (2013) Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison. Antimicrob Agents Chemother 57(10):5067–5079PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    McDowell JA, Chittick GE, Ravitch JR, Polk RE, Kerkering TM, Stein DS (1999) Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob Agents Chemother 43(12):2855–2861PubMedPubMedCentralGoogle Scholar
  36. 36.
    Boelaert JR, Dom GM, Huitema AD, Beijnen JH, Lange JM (2002) The boosting of didanosine by allopurinol permits a halving of the didanosine dosage. AIDS 16(16):2221–2223PubMedCrossRefGoogle Scholar
  37. 37.
    Videx (2009) Prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020156s044lbl.pdf. Accessed 19 June 2016
  38. 38.
    Ray AS, Olson L, Fridland A (2004) Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob Agents Chemother 48(4):1089–1095PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Emtriva (2012) Prescribing information. Available at: http://www.gilead.com/~/media/files/pdfs/medicines/hiv/emtriva/emtriva_pi.pdf. Accessed 19 June 2016
  40. 40.
    Epivir (2013) Prescribing information. Available at: https://www.viivhealthcare.com/media/32160/us_epivir.pdf. Accessed 19 June 2016
  41. 41.
    Zerit (2008) Prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020412s029,020413s020lbl.pdf. Accessed 19 June 2016
  42. 42.
    Rainey PM, Friedland G, McCance-Katz EF, Andrews L, Mitchell SM, Charles C et al (2000) Interaction of methadone with didanosine and stavudine. J Acquir Immune Defic Syndr 24(3):241–248PubMedCrossRefGoogle Scholar
  43. 43.
    Viread (2012) Prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021356s042,022577s002lbl.pdf. Accessed 19 June 2016
  44. 44.
    Baker J, Rainey PM, Moody DE, Morse GD, Ma Q, McCance-Katz EF (2010) Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir. Am J Addict 19(1):17–29PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Wenning LA, Friedman EJ, Kost JT, Breidinger SA, Stek JE, Lasseter KC et al (2008) Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemother 52(9):3253–3258PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Barbier O, Turgeon D, Girard C, Green MD, Tephly TR, Hum DW et al (2000) 3′-azido-3′-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos 28(5):497–502PubMedGoogle Scholar
  47. 47.
    Trapnell CB, Klecker RW, Jamis-Dow C, Collins JM (1998) Glucuronidation of 3′-azido-3′-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid. Antimicrob Agents Chemother 42(7):1592–1596PubMedPubMedCentralGoogle Scholar
  48. 48.
    Belanger AS, Caron P, Harvey M, Zimmerman PA, Mehlotra RK, Guillemette C (2009) Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos 37(9):1793–1796PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Uchaipichat V, Winner LK, Mackenzie PI, Elliot DJ, Williams JA, Miners JO (2006) Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol 61(4):427–439PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Raungrut P, Uchaipichat V, Elliot DJ, Janchawee B, Somogyi AA, Miners JO (2010) In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans. J Pharmacol Exp Ther 334(2):609–618PubMedCrossRefGoogle Scholar
  51. 51.
    Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB et al (2004) Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 32(4):413–423PubMedCrossRefGoogle Scholar
  52. 52.
    Ethell BT, Anderson GD, Burchell B (2003) The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases. Biochem Pharmacol 65(9):1441–1449PubMedCrossRefGoogle Scholar
  53. 53.
    Retrovir (2008) Prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019910s033lbl.pdf. Accessed 19 June 2016
  54. 54.
    Gallicano KD, Sahai J, Shukla VK, Seguin I, Pakuts A, Kwok D et al (1999) Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. Br J Clin Pharmacol 48(2):168–179PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Ouellet D, Hsu A, Qian J, Locke CS, Eason CJ, Cavanaugh JH et al (1998) Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 46(2):111–116PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Hulskotte EG, Feng HP, Xuan F, van Zutven MG, Treitel MA, Hughes EA et al (2013) Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis 56(5):718–726PubMedCrossRefGoogle Scholar
  57. 57.
    Zheng J (2002) Clinical pharmacology and biopharmaceutics review (21–567). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_BioPharmr_P1.pdf. Accessed 6 June 2016
  58. 58.
    Reyataz (2015) Prescribing information. Available at: http://packageinserts.bms.com/pi/pi_reyataz.pdf. Accessed 19 June 2016
  59. 59.
    Zhang X, Jones DR, Hall SD (2009) Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition. Drug Metab Dispos 37(1):150–160PubMedCrossRefGoogle Scholar
  60. 60.
    Krishna G, Moton A, Ma L, Martinho M, Seiberling M, McLeod J (2009) Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers. J Acquir Immune Defic Syndr 51(4):437–444PubMedCrossRefGoogle Scholar
  61. 61.
    Michaud V, Turgeon J (2010) Assessment of competitive and mechanism-based inhibition by clarithromycin: use of domperidone as a CYP3A probe-drug substrate and various enzymatic sources including a new cell-based assay with freshly isolated human hepatocytes. Drug Metab Lett 4(2):69–76PubMedCrossRefGoogle Scholar
  62. 62.
    Prezista (2015) Prescribing information. Available at: https://www.prezista.com/sites/default/files/pdf/us_package_insert.pdf. Accessed 19 June 2016
  63. 63.
    Chapron B, Risler L, Phillips B, Collins C, Thummel K, Shen D (2015) Reversible, time-dependent inhibition of CYP3A-mediated metabolism of midazolam and tacrolimus by telaprevir in human liver microsomes. J Pharm Pharm Sci 18(1):101–111PubMedCrossRefGoogle Scholar
  64. 64.
    Magnusson MO, Dahl ML, Cederberg J, Karlsson MO, Sandstrom R (2008) Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. Clin Pharmacol Ther 84(1):52–62PubMedCrossRefGoogle Scholar
  65. 65.
    Lexiva (2009) Prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021548s021,022116s005lbl.pdf. Accessed 19 June 2016
  66. 66.
    Decker CJ, Laitinen LM, Bridson GW, Raybuck SA, Tung RD, Chaturvedi PR (1998) Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J Pharm Sci 87(7):803–807PubMedCrossRefGoogle Scholar
  67. 67.
    Iribarne C, Berthou F, Carlhant D, Dreano Y, Picart D, Lohezic F et al (1998) Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab Dispos 26(3):257–260PubMedGoogle Scholar
  68. 68.
    Bruggemann RJ, van Luin M, Colbers EP, van den Dungen MW, Pharo C, Schouwenberg BJ et al (2010) Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers. J Antimicrob Chemother 65(10):2188–2194PubMedCrossRefGoogle Scholar
  69. 69.
    Rodrigues AD, Roberts EM, Mulford DJ, Yao Y, Ouellet D (1997) Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab Dispos 25(5):623–630PubMedGoogle Scholar
  70. 70.
    Park JE, Kim KB, Bae SK, Moon BS, Liu KH, Shin JG (2008) Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. Xenobiotica 38(9):1240–1251PubMedCrossRefGoogle Scholar
  71. 71.
    Crixivan (2008) Prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020685s066lbl.pdf. Accessed 19 June 2016
  72. 72.
    Viracept (2011) Prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020778s035,020779s056,021503s017lbl.pdf. Accessed 19 June 2016
  73. 73.
    Kaletra (2013) Prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021226s037lbl.pdf. Accessed 19 June 2016
  74. 74.
    van der Lee MJ, Dawood L, ter Hofstede HJ, de Graaff-Teulen MJ, van Ewijk-Beneken Kolmer EW, Caliskan-Yassen N et al (2006) Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther 80(2):159–168PubMedCrossRefGoogle Scholar
  75. 75.
    Lim ML, Min SS, Eron JJ, Bertz RJ, Robinson M, Gaedigk A et al (2004) Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr 36(5):1034–1040PubMedCrossRefGoogle Scholar
  76. 76.
    Invirase (2010) Prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020628s032,021785s009lbl.pdf. Accessed 19 June 2016
  77. 77.
    Norvir (2005) Prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020659s034,020945s017lbl.pdf. Accessed 19 June 2016
  78. 78.
    Aptivus (2009) Prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021814s006,022292s001lbl.pdf. Accessed 19 June 2016
  79. 79.
    Fuzeon (2011) Prescribing information. Available at: http://hivdb.stanford.edu/pages/linksPages/ENF_PI.pdf. Accessed 19 June 2016
  80. 80.
    Selzentry (2007) Prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022128lbl.pdf. Accessed 19 June 2016
  81. 81.
    Vourvahis M, Plotka A (2013) Mendes da Costa L, Fang A, Heera J. Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects. Antimicrob Agents Chemother 57(12):6158–6164PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Hyland R, Dickins M, Collins C, Jones H, Jones B (2008) Maraviroc: in vitro assessment of drug-drug interaction potential. Br J Clin Pharmacol 66(4):498–507PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Vourvahis M, Plotka A, Kantaridis C, Fang A, Heera J (2014) The effects of boceprevir and telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers. J Acquir Immune Defic Syndr 65(5):564–570PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ (1999) Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 27(12):1488–1495PubMedGoogle Scholar
  85. 85.
    Tivicay (2013) Prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204790lbl.pdf. Accessed 19 June 2016
  86. 86.
    Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E et al (2013) In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos 41(2):353–361PubMedCrossRefGoogle Scholar
  87. 87.
    Bruce RD, Moody DE, Fang WB, Chodkowski D, Andrews L, Friedland GH (2011) Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone. Am J Drug Alcohol Abuse 37(4):224–228PubMedCrossRefGoogle Scholar
  88. 88.
    Kiang TK, Wilby KJ, Ensom MH (2013) Telaprevir: clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions. Clin Pharmacokinet 52(7):487–510PubMedCrossRefGoogle Scholar
  89. 89.
    Vitekta (2014) Prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203093s000lbl.pdf. Accessed 19 June 2016
  90. 90.
    Isentress (2011) Prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022145s018lbl.pdf. Accessed 19 June 2016

Copyright information

© Springer Science+Business Media Singapore 2016

Authors and Affiliations

  • Tony K. L. Kiang
    • 1
  • Kyle John Wilby
    • 2
  • Mary H. H. Ensom
    • 1
  1. 1.Faculty of Pharmaceutical SciencesThe University of British ColumbiaVancouverCanada
  2. 2.College of PharmacyQatar UniversityDohaQatar

Personalised recommendations